Yusheng Han Buys 250,000 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 250,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was purchased at an average price of $8.00 per share, with a total value of $2,000,000.00. Following the purchase, the director directly owned 18,379,186 shares of the company’s stock, valued at $147,033,488. The trade was a 1.38% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of BNR stock opened at $9.82 on Friday. The stock’s fifty day moving average is $12.35 and its 200-day moving average is $19.96. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. The stock has a market capitalization of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $3.23 and a 52 week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The business had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Marshall Wace LLP bought a new stake in shares of Burning Rock Biotech during the fourth quarter worth approximately $220,000. Renaissance Technologies LLC lifted its holdings in Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares during the period. Prospera Financial Services Inc lifted its holdings in Burning Rock Biotech by 26.0% in the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares during the period. Finally, Crcm LP boosted its stake in Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after acquiring an additional 26,809 shares during the last quarter. Institutional investors own 30.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BNR shares. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Burning Rock Biotech presently has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.